Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Donna Matzov *Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Aoife RyderSchool of Medicine and School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
Kanhaya LalSchool of Pharmacy, Queen's University Belfast, Belfast, UK.
Dmitry S KarlovSchool of Pharmacy, Queen's University Belfast, Belfast, UK.
Georges ChalhoubDepartment of Pharmacology and Therapeutics, University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Sherrington Building, Liverpool, UK.
Eamon P MulvaneyATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Ireland.ORCID http://orcid.org/0000-0003-3661-2116
B Therese KinsellaATXA Therapeutics Limited, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Ireland.ORCID http://orcid.org/0000-0003-3072-941X
Peter J McCormickDepartment of Pharmacology and Therapeutics, University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Sherrington Building, Liverpool, UK.ORCID http://orcid.org/0000-0002-2225-5181
Martin CaffreySchool of Medicine and School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland. martin.caffrey@tcd.ie.ORCID http://orcid.org/0000-0002-2931-4551
Moran Shalev-BenamiDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel. moransb@weizmann.ac.il.ORCID http://orcid.org/0000-0001-6902-1924
Funding
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 949364Irish Research Council for Science, Engineering and Technology (IRCSET) GOIPG/2019/3074RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/R007101/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/T022175/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/W03204X/1Science Foundation Ireland (SFI) 16/IA/4435Science Foundation Ireland (SFI) 22/FFP-A/10278
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structural and dynamic insights into agonist recognition and function of the thromboxane A · full record | OpenQuestion